These are the opening talks from this year's ODN Stakeholder Event from Mark Gillyon-Powell, Head of Programme for HCV Elimination, NHS England and Prof Graham Foster, National Clinical Lead for ODNs, NHS England.
The talks gives a national overview on hepatitis C elimination efforts in England and how COVID-19 has impacted these. Professor Guruprasad Aithal, President of the British Association for the Study of the Liver (BASL) chaired the event.
We will be publishing a written summary of the other presentations from this event soon.
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Download
This paper reports on the results of a 2011 EASL meeting and subsequent dialogue with patient groups and relevant experts in Europe. It summarises the current knowledge of HCV infection and the brain; prevalence, course, and neurobiology of IFN-a associated psychiatric side effects; possible risk factors for IFN-a associated depression and suicide attempts; psychiatric management of HCV infected patients before and during antiviral treatment; prevention of IFN- a associated psychiatric side effects; and psychiatric aspects of the new antivirals.
